Medicus Pharma Ltd. (MDCXW) income statement

MDCXWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as MDCX

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026Score 5/30

$0.21+0.00 (0.00%)

Close on Oct 30, 2026Market cap $118.78MP/E –Yield –

Medicus Pharma Ltd. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q2 2026 2026-06-30	TTM Q1 2026 2026-03-31	TTM FY 2025 2025-12-31	TTM Q3 2025 2025-09-30	TTM Q2 2025 2025-06-30	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31
Research & Development	12	8.42	7.72	6.50	5.38	5.21	3.53
General & Administrative	18	16	18	9.92	12	9.39	7.65
Operating Expenses	28	22	34	15	17	15	11
Operating Income	-28	-22	-34	-15	-17	-15	-11
Other Non-Operating Income	-1.60	-1.55	-1.09	-0.64	-0.03	0.05	0.03
Net Income incl. Noncontrolling Interests	-45	-39	-35	-31	-17	-15	-11
Minority Interest in Earnings	-0.07	0.00	0.00	0.00	0	–	0
Net Income	-57	-51	-47	-36	-17	-15	-11
Net Income to Common	–	-51	-47	-36	-17	-15	-11
EPS (Basic)(per share)	-2.45	-2.67	-2.74	-2.28	-1.40	-1.41	-1.16
EPS (Diluted)(per share)	-2.45	-2.67	-2.74	-2.28	-1.40	-1.41	-1.16
Shares Outstanding (Basic, Weighted)(shares)	30	20	17	14	12	10	9.62
Shares Outstanding (Diluted, Weighted)(shares)	30	20	17	14	12	10	9.62
Net Interest Income	–	–	-0.20	–	–	–	0.03

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -3083.1%

Financial strength

Current ratio: 1.57
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 140.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –